923P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial.
Saved in:
| Title: | 923P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial. |
|---|---|
| Authors: | Le Tourneau, C.1 (AUTHOR), Ghiringhelli, F.2 (AUTHOR), Saada, E.B.3 (AUTHOR), Chaltiel, R.4 (AUTHOR), Vansteene, D.5 (AUTHOR), Durando, X.6 (AUTHOR), You, B.7 (AUTHOR), Borel, C.8 (AUTHOR), Bigot, F.9 (AUTHOR), Abdeddaim, C.10 (AUTHOR), Marret, G.11 (AUTHOR), Jeannot, E.12 (AUTHOR), Guerini Rocco, E.13 (AUTHOR), Frige, G.14 (AUTHOR), Servant, N.15 (AUTHOR), Dupain, C.16 (AUTHOR), Kamal, M.16 (AUTHOR), Legrand, F.17 (AUTHOR), Jimenez, M.17 (AUTHOR), Filleron, T.18 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS583-S583. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.09.2067 |
